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Recent emergence of a virulent strain of Clostridium
difficile demonstrates the importance of tracking C. difficile
incidence locally. Our survey of New Jersey hospitals doc-
umented increases in the rates of C. difficile disease (by 2-
fold), C. difficile–associated complications (by 7-fold), and
C. difficile outbreaks (by 12-fold) during 2000–2004.
C
lostridium difficile, a gram-positive organism, is the
most common cause of nosocomial infectious diarrhea
in the United States (1). In 2005, the Centers for Disease
Control and Prevention (CDC) reported on a new, epidem-
ic, toxin gene–variant strain of C. difficile on the basis of a
study of isolates collected from hospitals in multiple states,
including New Jersey. CDC recommended that inpatient
healthcare facilities track the incidence of C.
difficile–associated disease (CDAD), including the clinical
outcomes of patients (2).
The Study
To estimate the incidence of CDAD in hospitalized
patients in New Jersey, we conducted a retrospective sur-
vey of acute-care hospitals. An Internet-based question-
naire was distributed to all 81 New Jersey hospitals in
early 2005; hospitals that did not respond were contacted
by telephone or electronic mail. We collected information
on hospital characteristics, the number of CDAD cases, C.
difficile–positive laboratory test results, C. difficile–associ-
ated complications, deaths due to any cause within 30 days
of diagnosis with C. difficile infection, healthcare-associat-
ed C. difficile outbreaks, recurrent CDAD cases, diagnos-
tic test methods, and surveillance activities. The proportion
of community- versus healthcare-acquired cases was not
assessed objectively; however, respondents provided their
perceptions regarding trends. No individual patient infor-
mation was obtained.
ACDAD case was defined as a patient with symptoms
of diarrhea and at least 1 of the following: positive toxin
assay result, diagnosis of pseudomembranous colitis on
sigmoidoscopy or colonoscopy, or histopathologic diagno-
sis. An outbreak was defined as >3 cases of healthcare-
associated CDAD in the same general area within 7 days.
Acomplicated case was defined as a patient with CDAD in
whom toxic megacolon, perforation of the colon, colecto-
my, or shock requiring vasopressor therapy subsequently
developed within 30 days after diagnosis with CDAD. The
definition of recurrent CDAD and the method of laborato-
ry diagnoses were determined by each hospital.
Data were analyzed by using EpiInfo version 3.3.2
(CDC, Atlanta, GA, USA) and SAS version 8.02 (SAS
Institute, Cary, NC, USA). The medians, means, ranges,
frequencies, and totals reported are based on actual
responses to the survey questions; hospitals that did not
answer a question were excluded from the analysis of
responses to that question. Tests for linear trend over the
study period were performed by using linear regression.
We also examined the association between CDAD rates
and staffing levels of infection-control professionals
(ICPs) by using a Poisson regression model.
Of the 81 hospitals contacted, 58 (72%), located in 20
of 21 New Jersey counties, responded to the survey. The
median bed capacity of participating hospitals was 281
(range 77–683), and the median number of full-time equiv-
alent ICPs per 250 beds was 1.2 (range 0–3).
During 2000–2004, participating hospitals reported a
total of 13,394 CDAD cases. The mean annual rate of
CDAD increased from 3.7/1,000 admissions in 2000 to
7.7/1,000 admissions in 2004, which represented a >2-fold
increase in CDAD rates during the 5-year period (p<0.05,
Table 1). Of the hospitals that responded, the percentage
that did not identify CDAD cases decreased from 55% in
2000 to 25% in 2004. A significant inverse association
existed between the number of ICPs per 250 beds and
CDAD rates in 2004 (p = 0.05, Figure). Table 1 indicates
a similar increasing trend in the rates of positive C. diffi-
cile test results, CDAD outbreaks, complications, annual
30-day crude mortality (deaths due to any cause), and
recurrent CDAD infection. Hospitals differed widely in
their case definitions for recurrent cases. Most used an
arbitrary period (from first episode to CDAD relapse),
varying from 6 weeks to 1 year, to define a recurrent case.
Most (60%) respondents thought that the number of
cases of community-acquired CDAD increased in 2004
compared with previous years. Smaller proportions of
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rent cases (55%), healthcare-acquired cases (40%), com-
plicated cases (28%), and deaths (19%) during the same
period.
Hospital laboratories most commonly used enzyme
immunoassay (EIA) tests for toxins A and B to identify C.
difficile (88%), followed by stool culture (16%), cytotoxin
testing using tissue culture (7%), and EIAfor toxin A(7%).
Forty (69%) hospital laboratories reported having written
institutional policies for correct specimen collection, stor-
age, and transportation of specimens for CDAD diagnosis.
Surveillance methods used by hospitals to track CDAD in
their institutions are detailed in Table 2.
The survey design had several limitations. First, the
analysis was designed to measure the overall incidence of
CDAD associated with acute-care hospitalization, regard-
less of acquisition site, and we did not distinguish between
community- and healthcare-associated infections. Second,
we did not collect information on nonresponding hospitals
and therefore are unable to determine if substantial differ-
ences existed between responding and nonresponding hos-
pitals. Third, the rates of CDAD infections were calculated
from data provided by the hospitals; hospitals might not
have consistently followed the case definitions that were
provided for reporting. We also reviewed administrative
(i.e., universal billing) data as a secondary data source and
found similar trends to those observed in this study.
However, this process has multiple weaknesses, including
ambiguities in coding and misclassification, which limit its
utility for surveillance (3). Finally, enhanced awareness of
the disease among clinicians and ICPs might have con-
tributed to increased reporting during the 5-year period.
Conclusions
Our results demonstrate that CDAD rates and associ-
ated complications rose rapidly among New Jersey hospi-
tals during 2000–2004. How much of the increase reflects
rising awareness and how much is a true increase in inci-
dence is unclear. Nevertheless, the trend is dramatic and
consistent with published reports in the United States,
Canada, and Europe that evaluated CDAD rates during
earlier periods (4–7). 
Our observation that a higher ICP staffing level was
associated with lower CDAD rates is consistent with pre-
vious studies demonstrating that a higher ICP-to-bed ratio
is associated with reduction in rates of healthcare-acquired
infections (8–10). We recommend that hospitals ensure
that their infection-control programs employ sufficient
personnel and other resources to implement adequate
infection-control practices, with the goal of decreasing
CDAD rates in their institutions.
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Figure. Boxplot of Clostridium difficile rates by number of infection
control professionals per 250 beds, 2004. Each box shows the
median, quartiles, and extreme values.In terms of surveillance activities, almost all partici-
pating hospitals tracked C. difficile laboratory results.
However, a relatively low percentage of hospitals routine-
ly monitored CDAD complications and deaths. Given
recent reports of the emergence of hypertoxin-producing
C. difficile strains that are more treatment-resistant and
potentially more virulent than other strains (2), we recom-
mend that hospitals implement or continue comprehensive
surveillance programs to track the incidence of both
healthcare-acquired and community-acquired CDAD, as
well as patient outcomes. Surveillance of these entities will
allow ICPs to identify quickly changes in CDAD incidence
and severity that could be associated with the introduction
of new, more virulent strains. In addition, rapid changes in
incidence and detected outbreaks should be reported to
public health officials.
Despite the survey’s limitations, the estimates provid-
ed from this substantial sample of acute-care hospitals are
useful for hospitals to develop appropriate CDAD policies
and can serve as comparison data for future infection pre-
vention and control efforts in New Jersey and other states.
Indeed, given the recent increase in the extent of C. diffi-
cile death and illness in North America and Europe, the
findings in this study show that CDAD is an emerging
problem, worthy of substantial investment in effective
infection-control and monitoring systems.
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